Francesca Romana Lepri

Francesca Romana Lepri

Auto-generated profile, based on publicly available information

Francesca Romana Lepri

Laboratory of Medical Genetics Translational Cytogenomics Research Unit Bambino Gesù Children's Hospital IRCCS Rome Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2007 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BPBhaswati Pandit
Bhaswati Pandit
ASAnna Sarkozy
Anna Sarkozy
LPLen A Pennacchio
Len A Pennacchio
CCClaudio Carta
Claudio Carta
KOKimihiko Oishi
Kimihiko Oishi
BGBruce D Gelb
Bruce D Gelb

3 December 2006 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MTMarco Tartaglia
Marco Tartaglia
LPLen A Pennacchio
Len A Pennacchio
CZChen Zhao
Chen Zhao
KYKamlesh K Yadav
Kamlesh K Yadav
VFValentina Fodale
Valentina Fodale
BGBruce D Gelb
Bruce D Gelb

16 August 2009 in Nature Genetics
Verified
Journal Article
Open access
PDF file
VCViviana Cordeddu
Viviana Cordeddu
Elia Di SchiaviElia Di Schiavi
Elia Di Schiavi
LPLen A Pennacchio
Len A Pennacchio
AMAvi Ma’ayan
Avi Ma’ayan
ASAnna Sarkozy
Anna Sarkozy
MTMarco Tartaglia
Marco Tartaglia
Marco Tartaglia and colleagues report the identification of mutations of SHOC2 in individuals with Noonan-like syndrome with loose anagen hair. The mutations cause aberrantly acquired N-myristoylation of SHOC2 resulting in aberrant targeting of SHOC2 to the plasma membrane. SHOC2 is believed to function as a scaffold linking RAS to downstream signal transducers. N-myristoylation is a common form of co-translational protein fatty acylation resulting from the attachment of myristate to a required N-terminal glycine residue1,2. We show that aberrantly acquired N-myristoylation of SHOC2, a leucine-rich repeat–containing protein that positively modulates RAS-MAPK signal flow3,4,5,6, underlies a clinically distinctive condition of the neuro-cardio-facial-cutaneous disorders family. Twenty-five subjects with a relatively consistent phenotype previously termed Noonan-like syndrome with loose anagen hair (MIM607721)7 shared the 4A>G missense change in SHOC2 (producing an S2G amino acid substitution) that introduces an N-myristoylation site, resulting in aberrant targeting of SHOC2 to the plasma membrane and impaired translocation to the nucleus upon growth factor stimulation. Expression of SHOC2S2G in vitro enhanced MAPK activation in a cell type–specific fashion. Induction of SHOC2S2G in Caenorhabditis elegans engendered protruding vulva, a neomorphic phenotype previously associated with aberrant signaling. These results document the first example of an acquired N-terminal lipid modification of a protein causing human disease.

20 March 2009 in Human Mutation
Verified
Journal Article
Closed access
PDF file
ASAnna Sarkozy
Anna Sarkozy
CCClaudio Carta
Claudio Carta
SMSonia Moretti
Sonia Moretti
GZGiuseppe Zampino
Giuseppe Zampino
MDMaria C. Digilio
Maria C. Digilio
MTMarco Tartaglia
Marco Tartaglia
Noonan, LEOPARD, and cardiofaciocutaneous syndromes (NS, LS, and CFCS) are developmental disorders with overlapping features including distinctive facial dysmorphia, reduced growth, cardiac defects, skeletal and ectodermal anomalies, and variable cognitive deficits. Dysregulated RAS–mitogen‐activated protein kinase (MAPK) signal traffic has been established to represent the molecular pathogenic cause underlying these conditions. To investigate the phenotypic spectrum and molecular diversity of germline mutations affecting BRAF, which encodes a serine/threonine kinase functioning as a RAS effector frequently mutated in CFCS, subjects with a diagnosis of NS (N=270), LS (N=6), and CFCS (N=33), and no mutation in PTPN11, SOS1, KRAS, RAF1, MEK1, or MEK2, were screened for the entire coding sequence of the gene. Besides the expected high prevalence of mutations observed among CFCS patients (52%), a de novo heterozygous missense change was identified in one subject with LS (17%) and five individuals with NS (1.9%). Mutations mapped to multiple protein domains and largely did not overlap with cancer‐associated defects. NS‐causing mutations had not been documented in CFCS, suggesting that the phenotypes arising from germline BRAF defects might be allele specific. Selected mutant BRAF proteins promoted variable gain of function of the kinase, but appeared less activating compared to the recurrent cancer‐associated p.Val600Glu mutant. Our findings provide evidence for a wide phenotypic diversity associated with mutations affecting BRAF, and occurrence of a clinical continuum associated with these molecular lesions. Hum Mutat 0:1–8, 2009.

6 December 2009 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ICIon C Cirstea
Ion C Cirstea
KKKerstin Kutsche
Kerstin Kutsche
RDRadovan Dvorsky
Radovan Dvorsky
LGLothar Gremer
Lothar Gremer
CCClaudio Carta
Claudio Carta
MZMartin Zenker
Martin Zenker
Martin Zenker, Marco Tartaglia, Reza Ahmadian and colleagues report the identification of a restricted spectrum of NRAS mutations in individuals with Noonan syndrome. Functional testing revealed that the mutations confer enhanced stimulus-dependent MAPK activation. Noonan syndrome, a developmental disorder characterized by congenital heart defects, reduced growth, facial dysmorphism and variable cognitive deficits, is caused by constitutional dysregulation of the RAS-MAPK signaling pathway. Here we report that germline NRAS mutations conferring enhanced stimulus-dependent MAPK activation account for some cases of this disorder. These findings provide evidence for an obligate dependency on proper NRAS function in human development and growth.

1 August 2010 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SMSimone Martinelli
Simone Martinelli
ALAlessandro De Luca
Alessandro De Luca
ESEmilia Stellacci
Emilia Stellacci
CRCesare Rossi
Cesare Rossi
SCSaula Checquolo
Saula Checquolo
MTMarco Tartaglia
Marco Tartaglia